S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Bicycle Therapeutics (BCYC) Stock Forecast, Price & News

+0.93 (+6.20%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
578,898 shs
Average Volume
584,709 shs
Market Capitalization
$472.32 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bicycle Therapeutics logo

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.


Analyst Ratings for Bicycle Therapeutics
Expert Ratings for Bicycle Therapeutics
Recap: Bicycle Therapeutics Q1 Earnings
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$11.70 million
Book Value
$11.14 per share


Net Income
$-66.82 million
Net Margins
Pretax Margin




Free Float
Market Cap
$472.32 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.23 out of 5 stars

Medical Sector

337th out of 1,427 stocks

Pharmaceutical Preparations Industry

135th out of 683 stocks

Analyst Opinion: 4.4Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics
or view top-rated stocks.

Are investors shorting Bicycle Therapeutics?

Bicycle Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,470,000 shares, an increase of 27.3% from the April 30th total of 1,940,000 shares. Based on an average daily trading volume, of 572,500 shares, the days-to-cover ratio is currently 4.3 days.
View Bicycle Therapeutics' Short Interest

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Bicycle Therapeutics

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.23. The firm earned $3.86 million during the quarter, compared to the consensus estimate of $3.46 million. Bicycle Therapeutics had a negative net margin of 568.71% and a negative trailing twelve-month return on equity of 31.61%.
View Bicycle Therapeutics' earnings history

What price target have analysts set for BCYC?

10 Wall Street analysts have issued 12 month target prices for Bicycle Therapeutics' shares. Their forecasts range from $33.00 to $80.00. On average, they anticipate Bicycle Therapeutics' stock price to reach $62.00 in the next twelve months. This suggests a possible upside of 289.2% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?
Bicycle Therapeutics' management team includes the following people:
  • Dr. Kevin Lee M.B.A., Ph.D., CEO & Exec. Director (Age 53, Pay $1.16M)
  • Mr. Lee H. Kalowski M.B.A., MBA, Pres & CFO (Age 41, Pay $756.13k)
  • Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 71, Pay $40k)
  • Dr. Michael Skynner B.sc. Ph.d., Ph.D., Chief Technology Officer (Age 52, Pay $769.01k)
  • Dr. Nigel Crockett Ph.D., Chief Bus. Officer (Age 57, Pay $568.12k)
  • Dr. Dominic Smethurst M.A., M.D., Chief Medical Officer (Age 48, Pay $431.7k)
  • Dr. Christian Heinis, Scientific Founder
  • Mr. Alistair Milnes, Chief Operating Officer
  • Dr. Nicholas Keen Ph.D., Chief Scientific Officer (Age 54)
  • Mr. David E. Borah CFA, VP of Capital Markets & Investor Relations
What other stocks do shareholders of Bicycle Therapeutics own?
When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Deep Track Capital LP (6.26%), RTW Investments LP (4.30%), Tybourne Capital Management HK Ltd. (3.89%), SV Health Investors LLC (3.09%), First Light Asset Management LLC (3.00%) and Loomis Sayles & Co. L P (2.17%). Company insiders that own Bicycle Therapeutics stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends for Bicycle Therapeutics

Which institutional investors are selling Bicycle Therapeutics stock?

BCYC stock was sold by a variety of institutional investors in the last quarter, including Tybourne Capital Management HK Ltd., Acadian Asset Management LLC, First Light Asset Management LLC, Verition Fund Management LLC, Bellevue Group AG, Victory Capital Management Inc., BlackRock Inc., and Renaissance Technologies LLC. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kate Bingham, Kevin Lee, Lee Kalowski, Nigel Crockett, Pierre Legault, and Stephen B Alexander.
View insider buying and selling activity for Bicycle Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Deep Track Capital LP, Frazier Life Sciences Management L.P., RTW Investments LP, Great Point Partners LLC, Goldman Sachs Group Inc., Ghost Tree Capital LLC, Loomis Sayles & Co. L P, and Handelsbanken Fonder AB.
View insider buying and selling activity for Bicycle Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $15.93.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $472.32 million and generates $11.70 million in revenue each year. The company earns $-66.82 million in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 119 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.